These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10128045)

  • 1. Evaluation and financial impact of imipenem/cilastatin dosing in elderly patients based on renal function and body weight.
    Ritchie DJ; Reichley RM; Canaday KL; Bailey TC
    J Pharm Technol; 1993; 9(4):160-3. PubMed ID: 10128045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system.
    Pestotnik SL; Classen DC; Evans RS; Stevens LE; Burke JP
    Ann Pharmacother; 1993 Apr; 27(4):497-501. PubMed ID: 8477128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipenem-cilastatin dosing intervention program by pharmacists.
    Newcomb HW; Hill EM; McCarthy ID; Mostow SR
    Am J Hosp Pharm; 1992 May; 49(5):1133-5. PubMed ID: 1595741
    [No Abstract]   [Full Text] [Related]  

  • 4. [Evidence-based medicine, health costs and treatment of intra-abdominal infection].
    Badía X; Brosa M; Tellado JM
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():86-94. PubMed ID: 10605193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an imipenem/cilastatin target drug program.
    Abel SR; Guba EA
    DICP; 1991 Apr; 25(4):348-50. PubMed ID: 1926900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost comparison of intramuscular versus intravenous imipenem.
    Chin A; Gill MA; Ito MK; Yellin AE; Berne TV; Heseltine PN; Appleman MD
    Hosp Pharm; 1989 Nov; 24(11):905-9. PubMed ID: 10296145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative study of the cost-/effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study].
    Rodloff AC; Laubenthal HJ; Bastian A; Bestehorn K; Büchele G; Gaus W
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Apr; 31(3):172-80. PubMed ID: 8672620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease.
    Hassan Y; Al-Ramahi RJ; Aziz NA; Ghazali R
    Ann Pharmacother; 2009 Oct; 43(10):1598-605. PubMed ID: 19776297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriate but not cost effective ceftazidime use in a university hospital.
    Colburn PA; Carver PA; Montgomery PA; Alaniz C; Chaffee BW; Amesbury BK
    Hosp Pharm; 1989 Nov; 24(11):911-6, 928. PubMed ID: 10313376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjusting dosage intervals of intermittent intravenous ranitidine according to creatinine clearance: a cost-minimization analysis.
    Connelly JF
    Hosp Pharm; 1994 Nov; 29(11):992, 996-8, 1001. PubMed ID: 10138581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacoeconomics of meropenem versus imipenem/cilastatin].
    Marquina MC; Giráldez J; Idoate A
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():45-50. PubMed ID: 9410069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and tolerance of imipenem/cilastatin in the adjuvant treatment of surgery for peritonitis in patients over the age of 70 years].
    Janvier G; Carles J
    Ann Chir; 1993; 47(4):370-5. PubMed ID: 8352517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefoxitin use review.
    Lazor-Bajcar JM
    Can J Hosp Pharm; 1990 Oct; 43(5):221-5, xxxii. PubMed ID: 10107924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of antimicrobial drugs in adults before and after removal of a restriction policy.
    Himmelberg CJ; Pleasants RA; Weber DJ; Kessler JM; Samsa GP; Spivey JM; Morris TL
    Am J Hosp Pharm; 1991 Jun; 48(6):1220-7. PubMed ID: 1858800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative study of the cost-effectiveness of initial therapy with imipenem/cilastatin in secondary peritonitis].
    Rodloff AC; Kujath P; Lünstedt B; Gaus W
    Chirurg; 1998 Oct; 69(10):1093-100; discussion 1100. PubMed ID: 9833192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
    Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill.
    Hashimoto S; Honda M; Yamaguchi M; Sekimoto M; Tanaka Y
    ASAIO J; 1997; 43(1):84-8. PubMed ID: 9116359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital.
    Kabbara WK; Nawas GT; Ramadan WH
    Infect Drug Resist; 2015; 8():31-8. PubMed ID: 25848308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of clinical pharmacists to cefazolin utilization.
    Witte KW; Hatoum HT; Hoon TJ
    Hosp Formul; 1987 Aug; 22(8):737-41. PubMed ID: 10283405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.